CN Patent
CN107580495A — 单独和与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于治疗伴随系统性硬化症(SSc)的指溃疡(DU)的用途
Assigned to Bayer Pharma AG · Expires 2018-01-12 · 8y expired
What this patent protects
单独或与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于伴随纤维化疾病诸如系统性硬化症和硬皮病的指溃疡的预防和愈合的用途。
USPTO Abstract
单独或与PDE5抑制剂组合的sGC刺激剂、sGC活化剂用于伴随纤维化疾病诸如系统性硬化症和硬皮病的指溃疡的预防和愈合的用途。
Drugs covered by this patent
- Adempas (RIOCIGUAT) · Bayer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.